Which has preferable valuation & earnings, TENX or CTXR?

Tenax Therapeutics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tenax Therapeutics N/A N/A -$52.60M -$1.48 N/A Citius Pharmaceuticals N/A N/A -$37.43M -$1.67 N/A

Is TENX or CTXR more profitable?

Citius Pharmaceuticals' return on equity of -59.57% beat Tenax Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tenax Therapeutics N/A -61.54% -57.42% Citius Pharmaceuticals N/A -59.57% -34.47%

Does the media prefer TENX or CTXR?

In the previous week, Tenax Therapeutics had 13 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 15 mentions for Tenax Therapeutics and 2 mentions for Citius Pharmaceuticals. Tenax Therapeutics' average media sentiment score of 1.50 beat Citius Pharmaceuticals' score of 0.63 indicating that Tenax Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenax Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Citius Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CTXR or TLPH more profitable?

Citius Pharmaceuticals' return on equity of -59.57% beat Talphera's return on equity. Company Net Margins Return on Equity Return on Assets Citius Pharmaceuticals N/A -59.57% -34.47% Talphera N/A -87.28% -51.36%

Do analysts prefer CTXR or NTRB?

Citius Pharmaceuticals currently has a consensus price target of $5.00, suggesting a potential upside of 730.43%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Citius Pharmaceuticals is more favorable than Nutriband. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Citius Pharmaceuticals (CTXR) Competitors

$0.60 -0.03 (-4.28%)

As of 08/28/2026 04:00 PM Eastern

Compare

CTXR vs. TENX, TLPH, HRTX, NTRB, and CLNN

Should you buy Citius Pharmaceuticals stock or one of its competitors? Citius Pharmaceuticals's main competitors and comparable companies include Tenax Therapeutics (TENX), Talphera (TLPH), Heron Therapeutics (HRTX), Nutriband (NTRB), and Clene (CLNN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Citius Pharmaceuticals compare to Tenax Therapeutics?

Tenax Therapeutics (NASDAQ:TENX) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Citius Pharmaceuticals' return on equity of -59.57% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-61.54%	-57.42%
Citius Pharmaceuticals	N/A	-59.57%	-34.47%

In the previous week, Tenax Therapeutics had 13 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 15 mentions for Tenax Therapeutics and 2 mentions for Citius Pharmaceuticals. Tenax Therapeutics' average media sentiment score of 1.50 beat Citius Pharmaceuticals' score of 0.63 indicating that Tenax Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenax Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Citius Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tenax Therapeutics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$1.67	N/A

Tenax Therapeutics presently has a consensus target price of $14.00, suggesting a potential upside of 557.28%. Citius Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 730.43%. Given Citius Pharmaceuticals' higher possible upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Tenax Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Tenax Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 10.8% of Tenax Therapeutics shares are owned by company insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Tenax Therapeutics and Citius Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to Talphera?

Citius Pharmaceuticals (NASDAQ:CTXR) and Talphera (NASDAQ:TLPH) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Citius Pharmaceuticals has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, Talphera has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

Citius Pharmaceuticals currently has a consensus price target of $5.00, suggesting a potential upside of 730.43%. Talphera has a consensus price target of $3.00, suggesting a potential upside of 150.00%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Citius Pharmaceuticals is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Talphera has higher revenue and earnings than Citius Pharmaceuticals. Talphera is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$1.67	N/A
Talphera	$30K	2,076.40	-$14.29M	-$0.27	N/A

Citius Pharmaceuticals' return on equity of -59.57% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-59.57%	-34.47%
Talphera	N/A	-87.28%	-51.36%

In the previous week, Citius Pharmaceuticals had 1 more articles in the media than Talphera. MarketBeat recorded 2 mentions for Citius Pharmaceuticals and 1 mentions for Talphera. Talphera's average media sentiment score of 0.65 beat Citius Pharmaceuticals' score of 0.63 indicating that Talphera is being referred to more favorably in the news media.

Company	Overall Sentiment
Citius Pharmaceuticals	Positive
Talphera	Positive

16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 37.7% of Talphera shares are held by institutional investors. 5.0% of Citius Pharmaceuticals shares are held by company insiders. Comparatively, 3.5% of Talphera shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Citius Pharmaceuticals beats Talphera on 9 of the 14 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to Heron Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Heron Therapeutics has higher revenue and earnings than Citius Pharmaceuticals. Heron Therapeutics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$154.90M	0.40	-$20.19M	-$0.19	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$1.67	N/A

Heron Therapeutics has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market.

Heron Therapeutics currently has a consensus price target of $2.00, indicating a potential upside of 512.37%. Citius Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 730.43%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Heron Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

80.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 6.1% of Heron Therapeutics shares are held by insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Citius Pharmaceuticals has a net margin of 0.00% compared to Heron Therapeutics' net margin of -22.52%. Citius Pharmaceuticals' return on equity of -59.57% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-22.52%	-293.02%	-10.00%
Citius Pharmaceuticals	N/A	-59.57%	-34.47%

In the previous week, Citius Pharmaceuticals had 1 more articles in the media than Heron Therapeutics. MarketBeat recorded 2 mentions for Citius Pharmaceuticals and 1 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 1.89 beat Citius Pharmaceuticals' score of 0.63 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Heron Therapeutics	Very Positive
Citius Pharmaceuticals	Positive

Summary

Heron Therapeutics beats Citius Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to Nutriband?

Citius Pharmaceuticals (NASDAQ:CTXR) and Nutriband (NASDAQ:NTRB) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

Citius Pharmaceuticals has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market. Comparatively, Nutriband has a beta of 1.98, suggesting that its share price is 98% more volatile than the broader market.

Citius Pharmaceuticals has a net margin of 0.00% compared to Nutriband's net margin of -448.25%. Citius Pharmaceuticals' return on equity of -59.57% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-59.57%	-34.47%
Nutriband	-448.25%	-112.64%	-97.86%

In the previous week, Citius Pharmaceuticals had 1 more articles in the media than Nutriband. MarketBeat recorded 2 mentions for Citius Pharmaceuticals and 1 mentions for Nutriband. Nutriband's average media sentiment score of 1.87 beat Citius Pharmaceuticals' score of 0.63 indicating that Nutriband is being referred to more favorably in the news media.

Company	Overall Sentiment
Citius Pharmaceuticals	Positive
Nutriband	Very Positive

16.9% of Citius Pharmaceuticals shares are owned by institutional investors. Comparatively, 19.7% of Nutriband shares are owned by institutional investors. 5.0% of Citius Pharmaceuticals shares are owned by company insiders. Comparatively, 52.2% of Nutriband shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Nutriband has higher revenue and earnings than Citius Pharmaceuticals. Nutriband is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$1.67	N/A
Nutriband	$2.04M	26.59	-$8.23M	-$2.58	N/A

Citius Pharmaceuticals currently has a consensus price target of $5.00, suggesting a potential upside of 730.43%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Citius Pharmaceuticals is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Citius Pharmaceuticals beats Nutriband on 9 of the 15 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to Clene?

Citius Pharmaceuticals (NASDAQ:CTXR) and Clene (NASDAQ:CLNN) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

16.9% of Citius Pharmaceuticals shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 5.0% of Citius Pharmaceuticals shares are owned by company insiders. Comparatively, 28.3% of Clene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Citius Pharmaceuticals has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market. Comparatively, Clene has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market.

Citius Pharmaceuticals presently has a consensus price target of $5.00, indicating a potential upside of 730.43%. Clene has a consensus price target of $33.25, indicating a potential upside of 686.05%. Given Citius Pharmaceuticals' higher probable upside, equities analysts clearly believe Citius Pharmaceuticals is more favorable than Clene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Citius Pharmaceuticals had 1 more articles in the media than Clene. MarketBeat recorded 2 mentions for Citius Pharmaceuticals and 1 mentions for Clene. Clene's average media sentiment score of 1.89 beat Citius Pharmaceuticals' score of 0.63 indicating that Clene is being referred to more favorably in the news media.

Company	Overall Sentiment
Citius Pharmaceuticals	Positive
Clene	Very Positive

Citius Pharmaceuticals has a net margin of 0.00% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-59.57%	-34.47%
Clene	-20,063.96%	N/A	-137.04%

Clene has higher revenue and earnings than Citius Pharmaceuticals. Clene is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$1.67	N/A
Clene	$200K	271.78	-$26.17M	-$3.50	N/A

Summary

Clene beats Citius Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Citius Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTXR vs. The Competition

Export

Metric	Citius Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.53M	$12.17B	$7.21B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	-0.36	787.65	273.16	25.42
Price / Sales	N/A	756.04	629.76	95.09
Price / Cash	N/A	15.32	28.74	36.03
Price / Book	0.14	10.49	11.08	6.36
Net Income	-$37.43M	$2.83B	$3.48B	$349.79M
7 Day Performance	0.32%	0.39%	0.13%	-0.80%
1 Month Performance	-4.73%	5.34%	7.08%	4.13%
1 Year Performance	-54.73%	6.05%	24.67%	15.17%

Citius Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTXR Citius Pharmaceuticals	2.5391 of 5 stars	$0.60 -4.3%	$5.00 +730.4%	-54.7%	$16.53M	N/A	N/A	20
TENX Tenax Therapeutics	4.1403 of 5 stars	$1.85 +5.7%	$14.00 +656.8%	-64.4%	$65.49M	N/A	N/A	9	News Coverage Positive News Short Interest Increase
TLPH Talphera	2.7902 of 5 stars	$1.19 flat	$3.00 +152.1%	+121.8%	$61.77M	$30K	N/A	19
HRTX Heron Therapeutics	2.4452 of 5 stars	$0.32 +1.4%	$2.00 +519.6%	-75.8%	$60.41M	$151.18M	N/A	300	Positive News
NTRB Nutriband	0.4249 of 5 stars	$5.11 +9.4%	N/A	-31.1%	$56.72M	$2.04M	N/A	10	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTXR) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Citius Pharmaceuticals (CTXR) Competitors

CTXR vs. TENX, TLPH, HRTX, NTRB, and CLNN

How does Citius Pharmaceuticals compare to Tenax Therapeutics?

Summary

How does Citius Pharmaceuticals compare to Talphera?

Summary

How does Citius Pharmaceuticals compare to Heron Therapeutics?

Summary

How does Citius Pharmaceuticals compare to Nutriband?

Summary

How does Citius Pharmaceuticals compare to Clene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTXR vs. The Competition

Citius Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Citius Pharmaceuticals (CTXR) Competitors

CTXR vs. TENX, TLPH, HRTX, NTRB, and CLNN

How does Citius Pharmaceuticals compare to Tenax Therapeutics?

Is TENX or CTXR more profitable?

Does the media prefer TENX or CTXR?

Which has preferable valuation & earnings, TENX or CTXR?

Do analysts rate TENX or CTXR?

Which has more risk & volatility, TENX or CTXR?

Do institutionals & insiders have more ownership in TENX or CTXR?

Summary

How does Citius Pharmaceuticals compare to Talphera?

Which has more risk and volatility, CTXR or TLPH?

Do analysts prefer CTXR or TLPH?

Which has preferable earnings and valuation, CTXR or TLPH?

Is CTXR or TLPH more profitable?

Does the media refer more to CTXR or TLPH?

Do insiders & institutionals have more ownership in CTXR or TLPH?

Summary

How does Citius Pharmaceuticals compare to Heron Therapeutics?

Which has preferable valuation & earnings, HRTX or CTXR?

Which has more volatility & risk, HRTX or CTXR?

Do analysts prefer HRTX or CTXR?

Do insiders and institutionals hold more shares of HRTX or CTXR?

Is HRTX or CTXR more profitable?

Does the media favor HRTX or CTXR?

Summary

How does Citius Pharmaceuticals compare to Nutriband?

Which has more risk and volatility, CTXR or NTRB?

Is CTXR or NTRB more profitable?

Does the media refer more to CTXR or NTRB?

Do insiders & institutionals hold more shares of CTXR or NTRB?

Which has preferable earnings and valuation, CTXR or NTRB?

Do analysts prefer CTXR or NTRB?

Summary

How does Citius Pharmaceuticals compare to Clene?

Do institutionals and insiders believe in CTXR or CLNN?

Which has more volatility & risk, CTXR or CLNN?

Do analysts recommend CTXR or CLNN?

Does the media refer more to CTXR or CLNN?

Is CTXR or CLNN more profitable?

Which has higher earnings and valuation, CTXR or CLNN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTXR vs. The Competition

Citius Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools